COVID-19：富士フイルム､Eli Lillyから受託：抗体医薬の原薬製造（動画）：
COVID-19: Contracted by Fujifilm､Eli Lilly: Substance for antibody drugs:
COVID-19：Fujifilm和礼来公司签约：抗体药物的原料药生产
ー低・中所得国への普及を目指すー
富士フイルム：FUJIFILM Diosynth Biotech(FDB)
Eli Lilly社から、新型コロナウイルス感染症向け、抗体医薬品の原薬製造を受託しました。
FUJIFILM Diosynth Biotech(FDB)：
2021年4月より、デンマーク拠点にて製造を開始します。
Eli Lilly社のCOVID-19向け抗体医薬品を、低・中所得国への普及に貢献します。
富士フイルム [日本]
https://www.fujifilm.com/jp/ja/news/list/5537
FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody
for Low- and Middle-Income Countries
ILLERØD, Denmark,
October 8, 2020 —
FUJIFILM Diosynth Biotechnologies,
a world leading Contract Development and Manufacturing Organization (CDMO)
for biologics, viral vaccines and viral vectors,
today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP* facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.
The commercial manufacturing falls under the agreement between Lilly and the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator,
to supply potential Lilly therapeutic antibodies for the prevention and treatment of COVID-19.
The Therapeutics Accelerator is an initiative launched by
- the Gates Foundation,
- Wellcome,
- Mastercard
to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments
Fujifilm Global
https://www.fujifilm.com/news/n201009_02.html